Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Apr 18, 2024

(R) Notice of annual general meeting in Cantargia AB (publ)

Apr 17, 2024

Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition

Apr 10, 2024

Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal

Apr 8, 2024

Cantargia presents unique effects of nadunolimab in pancreatic cancer

Apr 2, 2024

Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis

Mar 27, 2024

Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia

Mar 14, 2024

(R) Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis

Mar 5, 2024

Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer

Feb 22, 2024

(R) Cantargia publishes Year-End Report for 2023

Feb 20, 2024

(R) Cantargia reports US regulatory approval to start pancreatic cancer phase IIb trial with nadunolimab

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye